When is chemotherapy in head and neck squamous cell carcinoma not indicated?
详细信息 查看全文
- 作者：Missak Haigentz Jr. (1)
Jan B. Vermorken (2)
Arlene A. Forastiere (3)
June Corry (4)
Jonathan J. Beitler (5)
Primo啪 Strojan (6)
Dana M. Hartl (7) (8)
Juan P. Rodrigo (10) (9)
Carol R. Bradford (11)
Alessandra Rinaldo (12)
Robert P. Takes (13)
William M. Mendenhall (14)
Ashok R. Shaha (15)
Gregory T. Wolf (11)
Alfio Ferlito (12)
1. Division of Oncology ; Department of Medicine ; Albert Einstein College of Medicine ; Montefiore Medical Center ; Bronx ; NY ; USA
2. Department of Medical Oncology ; Antwerp University Hospital ; Edegem ; Belgium
3. Department of Oncology ; The Sidney Kimmel Comprehensive Cancer Center ; Johns Hopkins University School of Medicine ; Baltimore ; MD ; USA
4. Division of Radiation Oncology ; Peter MacCallum Cancer Centre ; Melbourne ; VIC ; Australia
5. Departments of Radiation Oncology ; Otolaryngology ; Hematology and Medical Oncology ; Georgia Research Alliance Cancer Scientist ; Winship Cancer Institute ; Emory University ; Atlanta ; GA ; USA
6. Department of Radiation Oncology ; Institute of Oncology ; Ljubljana ; Slovenia
7. Department of Otolaryngology-Head and Neck Surgery ; Institut Gustave Roussy ; Villejuif Cedex ; France
8. Laboratoire de Phon茅tique et de Phonologie ; Sorbonne Nouvelle ; Paris ; France
10. Instituto Universitario de Oncolog铆a del Principado de Asturias ; Oviedo ; Spain
9. Department of Otolaryngology ; Hospital Universitario Central de Asturias ; Oviedo ; Spain
11. Department of Otolaryngology-Head and Neck Surgery ; University of Michigan ; Ann Arbor ; MI ; USA
12. ENT Clinic ; University of Udine ; Piazzale S. Maria della Misericordia ; 33100 ; Udine ; Italy
13. Department of Otolaryngology-Head and Neck Surgery ; Radboud University Medical Center ; Nijmegen ; The Netherlands
14. Department of Radiation Oncology ; University of Florida ; College of Medicine ; Gainesville ; FL ; USA
15. Department of Surgery ; Memorial Sloan-Kettering Cancer Center ; New York ; NY ; USA - 刊名：European Archives of Oto-Rhino-Laryngology
- 出版年：2015
- 出版时间：April 2015
- 年：2015
- 卷：272
- 期：4
- 页码：781-787
- 全文大小：190 KB
- 参考文献：1. National Comprehensive Cancer Network (NCCN) Guidelines, Head and Neck Cancers, Version 2.2013
2. Pignon, JP, Ma卯tre, A, Maillard, E, Bourhis, J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92: pp. 4-14 CrossRef
3. Bourhis, J, Overgaard, J, Audry, H (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368: pp. 843-854 CrossRef
4. Beitler JJ, Zhang Q, Fu KK et al. Final results of local-regional control and late toxicity of RTOG 90-03; a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys (in press)
5. Ang, KK, Harris, J, Wheeler, R (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363: pp. 24-35 CrossRef
6. Bourhis, J, Sire, C, Graff, P (2012) Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 13: pp. 145-153 CrossRef
7. Overgaard, J, Hansen, HS, Specht, L (2003) Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362: pp. 933-940 CrossRef
8. Overgaard, J, Mohanti, BK, Begum, N (2010) Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol 11: pp. 553-560 CrossRef
9. Haigentz, M, Corry, J, Strojan, P, Ferlito, A (2012) Easing acceleration of head and neck chemoradiotherapy. Lancet Oncol 13: pp. 113-115 CrossRef
10. Liang, ZG, Zhu, XD, Zhou, ZR, Qu, S, Du, YQ, Jiang, YM (2012) Comparison of concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of 793 patients from 5 randomized controlled trials. Asian Pac J Cancer Prev 13: pp. 5747-5752 CrossRef
11. Holsinger, FC, Kies, MS, Diaz, EM (2009) Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol 27: pp. 1976-1982 CrossRef
12. Holsinger, FC, Lin, HY, Bassot, V, Laccourreye, O (2009) Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx. Cancer 115: pp. 3909-3918 CrossRef
13. Divi, V, Worden, FP, Prince, ME (2010) Chemotherapy alone for organ preservation in advanced laryngeal cancer. Head Neck 32: pp. 1040-1047 CrossRef
14. Forastiere, AA, Shaha, AR (2009) Chemotherapy alone for laryngeal preservation, is it possible?. J Clin Oncol 27: pp. 1933-1934 CrossRef
15. Haigentz, M, Silver, CE, Rinaldo, A, Ferlito, A (2010) Definitive chemotherapy: a new frontier in the fight against laryngeal cancer. Eur Arch Otorhinolaryngol 267: pp. 1-4 CrossRef
16. Robbins, KT, Kumar, P, Harris, J (2005) Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol 23: pp. 1447-1454 CrossRef
17. Nomura, K, Takahara, M, Katayama, A (2013) Intra-arterial cisplatin with concomitant radiation for advanced hypopharyngeal cancer. Laryngoscope 123: pp. 916-922 CrossRef
18. Kov谩cs, AF (2006) Response to intraarterial induction chemotherapy: a prognostic parameter in oral and oropharyngeal cancer. Head Neck 28: pp. 678-688 CrossRef
19. Regine, WF, Valentino, J, Arnold, SM (2001) High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 19: pp. 3333-3339
20. Spring, PM, Valentino, J, Arnold, SM (2005) Long-term results of hyperfractionated radiation and high-dose intraarterial cisplatin for unresectable oropharyngeal carcinoma. Cancer 104: pp. 1765-1771 CrossRef
21. Rasch, CR, Hauptmann, M, Schornagel, J (2010) Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: results of a randomized phase 3 trial. Cancer 116: pp. 2159-2165 CrossRef
22. Ackerstaff, AH, Rasch, CR, Balm, AJ (2012) Five-year quality of life results of the randomized clinical phase III (RADPLAT) trial, comparing concomitant intra-arterial versus intravenous chemoradiotherapy in locally advanced head and neck cancer. Head Neck 34: pp. 974-980 CrossRef
23. Janot, F, Raucourt, D, Benhamou, E (2008) Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 26: pp. 5518-5523 CrossRef
24. Choe, KS, Haraf, DJ, Solanki, A (2011) Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer 117: pp. 4671-4678 CrossRef
25. Strojan P, Corry J, Eisbruch A et al (2014) Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to re-irradiate. Head Neck. doi:10.1002/hed.23542
26. Gugic, J, Strojan, P (2013) Squamous cell carcinoma of the head and neck in the elderly. Rep Pract Oncol Radiother 18: pp. 16-25 CrossRef
27. Bonner, JA, Harari, PM, Giralt, J (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11: pp. 21-28 CrossRef
28. Haigentz, M, Cohen, EE, Wolf, GT, Strojan, P, Eisbruch, A, Ferlito, A (2012) The future of induction chemotherapy for head and neck squamous cell carcinoma. Oral Oncol 48: pp. 1065-1067 CrossRef
29. Haddad, R, O鈥橬eill, A, Rabinowits, G (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14: pp. 257-264 CrossRef
30. Hitt, R, Grau, JJ, L贸pez-Pousa, A (2014) A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25: pp. 216-225 CrossRef
31. Cohen, EEW, Karrison, T, Kocherginsky, M (2012) DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 30: pp. 5500
32. Argiris, A, Li, Y, Forastiere, A (2004) Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101: pp. 2222-2229 CrossRef
33. Argiris, A, Ghebremichael, M, Gilbert, J (2013) Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 31: pp. 1405-1414 CrossRef
34. Shiels, MS, Pfeiffer, RM, Gail, MH (2011) Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103: pp. 753-762 CrossRef
35. Haigentz, M (2005) Aerodigestive cancers in HIV infection. Curr Opin Oncol 17: pp. 474-478 CrossRef
36. McLemore, MS, Haigentz, M, Smith, RV (2010) Head and neck squamous cell carcinomas in HIV-positive patients: a preliminary investigation of viral associations. Head Neck Pathol 4: pp. 97-105 CrossRef
37. Haigentz, M, Jung, G, Garg, M, Owen, R, Schiff, B, Smith, RV (2006) Squamous cell carcinoma of the head and neck (SCCHN) in patients reporting human immunodeficiency virus (HIV) infection: a retrospective case series. J Clin Oncol 24: pp. 5570
38. Klein, EA, Guiou, M, Farwell, DG (2011) Primary radiation therapy for head-and-neck cancer in the setting of human immunodeficiency virus. Int J Radiat Oncol Biol Phys 79: pp. 60-64 CrossRef
39. Persad, GC, Little, RF, Grady, C (2008) Including persons with HIV infection in cancer clinical trials. J Clin Oncol 26: pp. 1027-1032 CrossRef
40. Weiss, SA, Gajavelli, S, Negassa, A, Sparano, JA, Haigentz, M (2011) Evaluation of cancer trial eligibility criteria (with focus on non-AIDS-defining cancers) for inclusion of persons with HIV infection. J Clin Oncol 29: pp. 6092 CrossRef
41. Ang, KK, Zhang, QE, Rosenthal, DI (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29: pp. 5500
42. Vermorken, JB, Mesia, R, Rivera, F (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: pp. 1116-1127 CrossRef
43. Vermorken, JB, Trigo, J, Hitt, R (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25: pp. 2171-2177 CrossRef
44. Fakhry, C, Westra, WH, Li, S (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100: pp. 261-269 CrossRef
45. Haigentz, M, Silver, CE, Corry, J (2009) Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol 266: pp. 1845-1855 CrossRef - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Otorhinolaryngology
Neurosurgery
Head and Neck Surgery - 出版者：Springer Berlin / Heidelberg
- ISSN：1434-4726
文摘